AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01069302
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel loading 300mg and maintenance 75mg for 7days
Trial: NCT04182321
Drug: Metformin & Entecavir
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adding sustained-release metformin hydrochloride (1000 mg, oral, once a day) for 24 weeks to the ongoing entecavir therapy (0.5 mg, oral, once a day)
Trial: NCT04182321
Drug: Placebo & Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adding placebo (oral, once a day) for 24 weeks to the ongoing entecavir therapy (0.5 mg, oral, once a day)
Trial: NCT00241514
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03488888
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound-Guided PEC block with 30 mL of 0.25% bupivacaine solution
Trial: NCT01866423
Drug: orteronel
RxNorm normalized name: Orteronel
DrugBank: Orteronel (DB12066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00517439
Drug: Copegus
RxNorm normalized name: Copegus
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000/1200mg po daily for 24 weeks
Trial: NCT00517439
Drug: Pegasys
RxNorm normalized name: Pegasys
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 180 micrograms sc weekly for 24 weeks
Trial: NCT00517439
Drug: Pegasys
RxNorm normalized name: Pegasys
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 90 micrograms sc weekly for 24 weeks
Trial: NCT00415064
Drug: Perifosine
RxNorm normalized name: Perifosine
DrugBank: Perifosine (DB06641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perifosine given in either 50 mg or 100 mg / day
Trial: NCT00415064
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide given in either 15 or 25 mg / day
Trial: NCT00415064
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone given in 20 mg / day
Trial: NCT00011414
Drug: Tariquidar
RxNorm normalized name: Tariquidar
DrugBank: Tariquidar (DB06240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV alone for 1 dose (Day -1), then in combo for rest of cycle (Day 1, etc). Given in combo with one of the following: Doxorubicin (50 mg/m2 IV over 15 min on day 1), Vinorelbine (20 mg/m2 IV over 10 min on days 1 and 8), or Docetaxel (75 mg/m2 IV over 60 min on day 1).
Trial: NCT01174004
Drug: pimavanserin tartrate
RxNorm normalized name: Pimavanserin tartrate
DrugBank: Pimavanserin (DB05316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pimavanserin tartrate, 40 mg, tablet, once daily by mouth for 6 weeks
Trial: NCT03367871
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV
Trial: NCT03367871
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously (IV) on day 1
Trial: NCT03849690
Drug: TAK-906
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-906 capsules.
Trial: NCT03849690
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole capsules.
Trial: NCT02103283
Drug: Teprotumumab
RxNorm normalized name: Teprotumumab
DrugBank: Teprotumumab (DB06343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Teprotumumab 20mg/kg administered by intravenous infusion every 3 weeks for 3 infusions
Trial: NCT03367871
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravenously (IV) on day 1
Trial: NCT03367871
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously (IV) on day 1
Trial: NCT03367871
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously (IV) on day 1
Trial: NCT00037648
Drug: Anakinra
RxNorm normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: anakinra
Trial: NCT00000262
Drug: 30% Nitrous oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000262
Drug: 0.4% Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000262
Drug: 0.2% sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03352453
Drug: Rapastinel
RxNorm normalized name: Rapastinel
DrugBank: Rapastinel (DB11801)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapastinel pre-filled syringes for weekly IV injections.
Trial: NCT03089944
Drug: Glecaprevir/Pibrentasvir
RxNorm normalized name: GLECAPREVIR/PIBRENTASVIR
DrugBank: Pibrentasvir (DB13878)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet
Trial: NCT00000429
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03430505
Drug: Albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal respiratory mechanics in spontaneous breathing will be analyzed by optoeletronic plethismography (OEP), followed by bronchial provocation with hypertonic saline solution 4.5%, another 45-second OEP uptake, 400 micrograms inhaled Albuterol, and a new uptake. All abstractions are preceded by a forced and slow spirometry maneuver. The entire procedure takes 1 hour.
Trial: NCT01840046
Drug: Interleukin-2
RxNorm normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will receive 4 cycles of recombinant interleukin 2 (aldesleukin, Proleukin ®) subcutaneously according to the following dosing schedule:~5 to 7 days (Monday to Friday) in weeks 1, 3, 6 and 9.~The dosage is as follows:~S1: 1.5 mille-International unit / day (D1 to D5), S3, S6 and S9: 3 mille-International unit /Jour (D1 to D5).
Trial: NCT04178993
Drug: Methamphetamine
RxNorm normalized name: Methamphetamine
DrugBank: Metamfetamine (DB01577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In each arm, subjects will receive doses of methamphetamine.
Trial: NCT04178993
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In each arm, subjects will receive methylphenidate capsules.
Trial: NCT04178993
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive duloxetine capsules in the duloxetine arm.
Trial: NCT00777530
Drug: Bosutinib (SKI-606)
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00983515
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of colchicine 0.6 mg administered alone at 7:00 a.m. on Day 1 after an overnight fast of at least 10 hours.
Trial: NCT00983515
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One 100 mg ritonavir capsule administered twice daily at 7:00 a.m. and 7:00 p.m. on Days 15 to 18 without regard to meals, then along with colchicine at 7:00 a.m. on Day 19 after an overnight fast of at least 10 hours; final dose of 100 mg ritonavir administered at 7:00 p.m. on Day 19
Trial: NCT00983515
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of colchicine 0.6 mg administered along with ritonavir at 7:00 a.m. on Day 19
Trial: NCT04371640
Drug: Sirolimus 1 MG/ML
RxNorm normalized name: sirolimus 1 MG/ML
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral solution
Trial: NCT00607113
Drug: Avastin
RxNorm normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15 mg/kg By Vein Over 90 Minutes Every 21 Days
Trial: NCT03849885
Drug: Benzoyl peroxide gel
RxNorm normalized name: Benzoyl Peroxide Gel
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Skin prep with Chlorohexidine wipes and BPO.
Trial: NCT02851407
Drug: Defibrotide
RxNorm normalized name: Defibrotide
DrugBank: Defibrotide (DB04932)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02120950
Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Eylea is administered as an intravitreal injection
Trial: NCT04620382
Drug: Midodrine
RxNorm normalized name: Midodrine
DrugBank: Midodrine (DB00211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Midodrine 5-10 mg, single oral dose
Trial: NCT01044212
Drug: Docusate
RxNorm normalized name: Docusate
DrugBank: Docusate (DB11089)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docusate 100mg BID
Trial: NCT00005631
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005631
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005631
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01655043
Drug: Regadenoson
RxNorm normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regadenoson will be infused intravenously 0.4 mg/5 mL (0.08 mg/mL) as a single bolus.
Trial: NCT01655043
Drug: gadofoveset trisodium
RxNorm normalized name: Gadofosveset Trisodium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects to receive 5 ml IV gadofoveset trisodium contrast (Ablavar) at both stress and rest.
Trial: NCT00075387
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IA
Trial: NCT00075387
Drug: Etoposide Phosphate
RxNorm normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00075387
Drug: Sodium Thiosulfate
RxNorm normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02818348
Drug: darunavir/cobicistat
RxNorm normalized name: darunavir/cobicistat 800 mg-150 mg ORAL TABLET
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 800/150 mg, once daily during 35 days + etravirine 400 mg, once daily during 14 days
Trial: NCT02818348
Drug: etravirine
RxNorm normalized name: Etravirine
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 400 mg, once daily during 28 days + darunavir/cobicistat 800/150 mg, once daily during 7 days
Trial: NCT00096499
Drug: ispinesib
RxNorm normalized name: Ispinesib
DrugBank: Ispinesib (DB06188)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00909545
Drug: Isradipine CR 5mg
RxNorm normalized name: Isradipine
DrugBank: Isradipine (DB00270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg dose: 1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily
Trial: NCT00909545
Drug: Isradipine CR 10mg
RxNorm normalized name: Isradipine
DrugBank: Isradipine (DB00270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg dose: 2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily
Trial: NCT00909545
Drug: Isradipine CR 20mg
RxNorm normalized name: Isradipine
DrugBank: Isradipine (DB00270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg dose: 4 Dynacirc CR 5mg tablets once daily
Trial: NCT05516784
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Comparison of platelet reactivity between clopidogrel and ticagrelor
Trial: NCT05516784
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of platelet reactivity between clopidogrel and ticagrelor
Trial: NCT04129788
Drug: Bisacodyl 5 milligram
RxNorm normalized name: Product containing precisely bisacodyl 5 milligram/1 each gastro-resistant oral tablet (clinical drug)
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: three doses taken, one per day on three consecutive days
Trial: NCT03995680
Drug: Mebendazole
RxNorm normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment with one of the two formulations of mebendazole. The only difference between both arms is the type of formulation of the drug: chewable versus swallowable tablet.
Trial: NCT02439320
Drug: Lasmiditan 100 mg
RxNorm normalized name: lasmiditan 100 MG
DrugBank: Lasmiditan (DB11732)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02439320
Drug: Lasmiditan 200 mg
RxNorm normalized name: lasmiditan 200 MG
DrugBank: Lasmiditan (DB11732)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02439320
Drug: Placebo (matches lasmiditan doses)
RxNorm normalized name: lasmiditan
DrugBank: Lasmiditan (DB11732)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04564612
Drug: Rabeprazole
RxNorm normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT03798054
Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010)
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Trial: NCT03798054
Drug: Insulin glargine (HOE901)
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Trial: NCT03798054
Drug: Lixisenatide (AVE0010)
DrugBank: Lixisenatide (DB09265)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Trial: NCT03798054
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Trial: NCT03798054
Drug: SGLT2 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:tablet~Route of administration: oral
Trial: NCT04564612
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT01218100
Drug: nebivolol and lisinopril (free combination)
RxNorm normalized name: valsartan and nebivolol
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nebivolol 5-mg and lisinopril 10-mg (nebivolol non-trade 5-mg tablet and overencapsulated lisinopril 10-mg tablet)/QD/oral administration/up to 12 weeks~nebivolol 20-mg and lisinopril 40-mg (nebivolol non-trade 20-mg tablet and overencapsulated lisinopril 40-mg tablet)/QD/oral administration/up to 10 weeks~nebivolol 5-mg and lisinopril 40-mg (nebivolol non-trade 5-mg tablet and overencapsulated lisinopril 40-mg tablet)/QD/oral administration/up to 6 weeks~nebivolol 20-mg and lisinopril 10-mg (nebivolol non-trade 20-mg tablet and overencapsulated lisinopril 10-mg tablet/QD/oral administration/up to 6 weeks
Trial: NCT01218100
Drug: nebivolol monotherapy
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nebivolol 5-mg (non-trade 5-mg tablet)/QD/oral administration/up to 12 weeks~nebivolol 10-mg (non-trade 10-mg tablet/QD/oral administration/for 1-week down-titration period only)~nebivolol 20-mg (non-trade 20-mg tablet)/QD/oral administration/up to 10 weeks
Trial: NCT01218100
Drug: lisinopril monotherapy
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lisinopril 10-mg (overencapsulated 10-mg tablet)/QD/oral administration/up to 12 weeks lisinopril 40-mg (overencapsulated 40-mg tablet)/QD/oral administration/up to 10 weeks
Trial: NCT01539343
Drug: Antimicrobial Solution
RxNorm normalized name: GAUZE,ANTIMICROBIAL
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antimicrobial solution, consisting of minocycline in combination with 30mg/ml of a chelator (EDTA) in 25% ethanol solution (HEAL solution), instilled in central venous catheter (CVC) catheter for 2 hours once daily for a minimum of 5 consecutive days. Lock therapy also received once weekly for two additional weeks.
Trial: NCT02952963
Drug: Colesevelam
RxNorm normalized name: Colesevelam
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004664
Drug: megestrol
RxNorm normalized name: Megestrol
DrugBank: Megestrol acetate (DB00351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00413920
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT02434354
Drug: pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg Subjects will receive 1 dose of neoadjuvant pembrolizumab, followed by complete resection and then a year of adjuvant pembrolizumab
Trial: NCT00144768
Drug: laronidase
RxNorm normalized name: Laronidase
DrugBank: Laronidase (DB00090)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: dose of 0.58mg/kg body weight IV every week
Trial: NCT01244581
Drug: Amoxicillin-clavulanate
RxNorm normalized name: amoxicillin-clavulanate
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate 40 mg/kg/day in two daily doses for 7 days
Trial: NCT03355560
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab 480 mg IV infusion
Trial: NCT04442256
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All patients will be administered subcutaneous doses of dupilumab in a biweekly fashion.
Trial: NCT05058105
Drug: FL058 500mg and Meropenem 1000mg（ IV 120min）
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D1 qd;~D2\~ D8 q8h;~D9 qd
Trial: NCT05058105
Drug: FL058 Placebo and Meropenem 1000mg（ IV 120min）
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D1 qd;~D2\~ D8 q8h;~D9 qd
Trial: NCT05058105
Drug: Meropenem 1000 mg （ IV 120min）
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D4 qd;
Trial: NCT05058105
Drug: Meropenem Placebo （ IV 120min）
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D4 qd;
Trial: NCT05058105
Drug: FL058 1000mg and Meropenem 1000mg （ IV 120min）
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D7 qd;~D8\~ D14 q8h;~D15 qd;
Trial: NCT05058105
Drug: FL058 Placebo and Meropenem 1000mg （ IV 120min）
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D7 qd;~D8\~ D14 q8h;~D15 qd;
Trial: NCT05058105
Drug: FL058 1000mg and Meropenem 2000mg （ IV 120min）
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D1 qd;~D2\~ D8 q8h;~D9 qd
Trial: NCT05058105
Drug: FL058 Placebo and Meropenem 2000m（ IV 120min）
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D1 qd;~D2\~ D8 q8h;~D9 qd
Trial: NCT05058105
Drug: FL058 1000mg and Meropenem 2000mg （ IV 180min）
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D1 qd;~D2\~ D8 q8h;~D9 qd
Trial: NCT05058105
Drug: FL058 Placebo and Meropenem 2000m（ IV 180min）
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D1 qd;~D2\~ D8 q8h;~D9 qd
Trial: NCT05058105
Drug: FL058 2000mg and Meropenem 2000mg（ IV 180min）
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D1 qd;~D2\~ D8 q8h;~D9 qd
Trial: NCT05058105
Drug: FL058 Placebo and Meropenem 2000mg（ IV 180min）
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D1 qd;~D2\~ D8 q8h;~D9 qd
Trial: NCT03630198
Drug: Corticosteroid with lidocaine
RxNorm normalized name: Doloracin with Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional corticosteroid injection
Trial: NCT03630198
Drug: Corticosteroid with normal saline
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional corticosteroid injection
Trial: NCT01068782
Drug: XL184
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: given orally as capsules
Trial: NCT04897919
Drug: Dihydroartemisinin-piperaquine 160 mg/20 mg Oral Tablet
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine is given as recommended by manufacturer and compared to the Artemether-lumefantrine group.
Trial: NCT00244348
Drug: Oxaliplatin (via HAI)
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01470690
Drug: boceprevir
RxNorm normalized name: Boceprevir
DrugBank: Boceprevir (DB08873)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Boceprevir 800 mg TID for 4 consecutive days + a single dose of 800 mg on Day 5